FDA approves Alembic’s generic Rexulti
Brexpiprazole is used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults, and in treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
Alembic has received permission from the Food and Drug Administration for brexpiprazole tablets, which is the generic of Otsuka’s Rexulti.
Brexpiprazole is an atypical antipsychotic used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults, and also used in treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
[Read more: Alembic gets FDA tentative OK for generic Bosulif]
Brexpiprazole tablets have a market value of roughly $ 2 billion for the 12 months ending September 2024, per IQVIA.
[Read more: Alembic unveils 2 generics]